Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Avatrombopag→

Avatrombopag Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
570406-98-3
Molecular formula
C29H34Cl2N6O3S2
Molecular weight
649.7 g/mol
Drug class
Thrombopoietin receptor agonistoral platelet-production stimulator
Mechanism of action
Binds and activates the thrombopoietin receptor (c-Mpl) on haematopoietic stem cells and megakaryocyte progenitors, stimulating proliferation and differentiation and increasing platelet production.
Indications / reported uses
  • Treatment of thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure
  • Treatment of persistent or chronic immune thrombocytopenia (ITP) in adults with an insufficient response to previous treatment; use is product-specific and is not intended to normalise platelet counts

Sources: US DailyMed — DOPTELET (avatrombopag) · FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Avatrombopag Environmental Risk Assessment (ERA) (the Avatrombopag ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.